Vaccine safety monitoring continues after a vaccine enters routine use. Clinical trials provide important evidence, but ongoing surveillance can examine use across larger and more varied populations. AusVaxSafety is Australia's active vaccine safety surveillance system, led by the National Centre for Immunisation Research and Surveillance and supported by Australian Government funding.
Active surveillance means the system seeks information after vaccination rather than relying only on people initiating a report. Its survey results contribute to safety assessment alongside other evidence. Understanding what those results measure helps patients read a dashboard without mistaking every reported symptom for a proven vaccine-caused injury.
How survey information contributes
AusVaxSafety collects online survey information from vaccine recipients after vaccination and analyses reporting patterns. The system covers vaccines used in Australian programs and publishes safety information. Its scope has expanded since it began monitoring influenza vaccination in young children in 2014.
A survey response provides information about someone's experience within the question's time frame. It may describe no symptoms, symptoms managed at home or a need for medical attention. Those categories help researchers organise the data, but they do not replace an individual clinical assessment. Read the exact survey question and reporting period before interpreting a chart's label or comparing results across groups.
Why asking people actively is useful
If a system hears only from people who choose to report a problem, it may have limited information about those who felt well. Actively inviting responses creates a different view of post-vaccination experiences. It can help identify unexpected changes in reporting patterns that warrant closer investigation.
That does not make every survey representative of every vaccinated person. Some people do not receive an invitation or do not respond, and respondents may differ from non-respondents. These limitations should be considered when interpreting the findings. Active and spontaneous reporting systems answer overlapping but distinct questions, so their results should be read together rather than treated as competing verdicts.
Read the denominator first
A percentage is meaningful only when you know who is included. Does the chart describe all doses given, all people invited to a survey or people who responded? Does it cover one age group, a particular vaccine or a particular period? A dashboard can be accurate while a screenshot stripped of those details becomes misleading.
For example, a percentage reporting any symptom among respondents is not automatically the rate of serious reactions among all vaccine recipients. The numerator and denominator are different. Before sharing a statistic, read the accompanying notes and preserve the context. If the context is missing, it is better to describe the uncertainty than fill the gap with an assumption.
A safety signal is a question to investigate
An unusual reporting pattern can prompt investigation. Researchers then consider the clinical details, expected background occurrence and other available evidence. A signal does not by itself establish causation, but it should not be dismissed simply because the cause is not yet known. Surveillance is designed to identify questions early enough for proper assessment.
Imagine a hypothetical increase in reports during a period when a separate infection is also circulating. Investigators would need to consider both explanations and the characteristics of the affected group. The example illustrates why careful analysis is needed; it is not a statement about a current signal. A dashboard alone rarely provides all the information needed for a causal conclusion.
Distinguish surveillance from your clinical care
Responding to a safety survey is not the same as booking a consultation or requesting emergency assistance. If you are unwell, seek the appropriate medical care first. For a suspected severe allergic reaction, call triple zero (000). Do not wait for a survey team or an online reporting service to contact you.
For a non-emergency concern, speak with a health professional and explain the vaccination date, symptom onset and progression. Keep any advice or discharge information. A clinician can assess your current condition and help decide whether a separate adverse event report is appropriate. Your immediate care should not depend on whether you happened to receive a survey invitation.
Victoria also has an adverse event pathway
SAEFVIC is Victoria's vaccine safety service for significant or unexpected events following immunisation and vaccine errors. Reporting is possible even when the cause is uncertain. It can provide clinical support and assist with planning future vaccination after a significant event. This is a different function from simply counting responses on a public dashboard.
Ask your vaccination provider to help if you are unsure how to report. Include factual details rather than feeling you must prove a diagnosis yourself. A useful report records what happened and what care was needed. Keep the distinction between a report, an assessment and a confirmed causal finding clear when discussing the event with others.
Use public results with appropriate confidence
Public surveillance information is valuable because it makes ongoing monitoring visible. It can show what is being measured and provide a route to more detailed findings. Look for the date, methods and population before comparing results with another publication. A reassuring pattern in one dataset cannot prove that every possible rare event is absent.
Equally, the existence of reports is not evidence that monitoring has failed. Collecting and investigating reports is part of what a safety system is meant to do. For your own vaccination decision, discuss relevant risks and benefits with a clinician. Use surveillance results as one source of evidence, interpreted alongside clinical guidance and your personal circumstances.
Sources & further reading
General information only. This article is educational and is not a substitute for personal medical advice. Your immuniser will confirm eligibility and contraindications on the day.
Ask your pharmacist or GP about suitability, benefits, risks and alternatives before making a treatment decision.